Journal of Clinical Oncology
Articles in this Issue
Linking comfort levels and knowledge gaps in hematology/oncology (HO) fellowship education: Insights from a multicenter survey.
9030 Background: HO fellowship programs lack standardized educational approaches. This can impact learning & self-assessment of learning gaps. This st...
Evaluation of expressional deregulations of micro RNAs and their potential role as molecular biomarkers in the diagnosis and prognosis of papillary thyroid carcinoma.
e18147 Background: Papillary thyroid carcinoma is the most prevalent type of thyroid cancer that accounts for more than 80% of all thyroid cancer cases. P...
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.
7514 Background: MM remains an incurable disease and resistance mechanisms are emerging. ISB 2001, a first-in-class trispecific T cell engager, redirects...
USP22 as promoter of Treg cell infiltration and modulator of immunotherapy efficacy through the PIAS1/P65/CCL22 pathway in pancreatic cancer.
4174 Background: Immune checkpoint inhibitors targeting PD-1 and CTLA-4 have shown success in various cancers; however, their efficacy in pancreatic cance...
Recent trends in reporting and methodological rigor of non-inferiority trials in oncology.
e23026 Background: Non-inferiority (NI) trials, which investigate if a new treatment is not significantly worse than the standard treatment, are increasin...
Multicentric evaluation of an artificial intelligence model to stratify stage II colon cancer patients from whole slide images.
3612 Background: Stage II colon cancer (IIA T3N0; IIB T4aN0; IIC T4bN0) represents nearly 25% of all colon cancers and includes a wide range of outcomes (...
A dose escalation and cohort expansion phase I/IIa study of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors.
TPS3166 Background: The oncofetal antigen 5T4 is overexpressed in many solid tumors with limited expression in normal adult tissues. Overexpression of 5T4...
Updated results of adjuvant toripalimab for locally advanced head and neck squamous cell carcinoma patients who achieved pathological complete response after neoadjuvant immunochemotherapy and surgery: A single-arm, phase II trial.
e18097 Background: Neoadjuvant immunochemotherapy (NICT) showed favorable efficacies and anticipated outcomes for locally advanced head and neck squamous...
Implications for sentinel lymph node biopsy (SLNB) omission in patients with early-stage node-negative HR+/HER2- breast cancer undergoing mastectomy.
580 Background: The SOUND and INSEMA trials demonstrated non-inferiority of SLNB omission in HR+/HER2- early-stage breast cancer (BC) patients with negati...
Navigating the cyber shift: The trends of electronic health record (EHR) engagement in oncology.
e13718 Background: Oncology has evolved in the cyber era of medicine. The 21 st Century Cures Act mandated patient access to medic...
<i>TP53</i> multihit mutations in 142 patients with MPN or AML: Comparative analysis of survival and risk factors.
e18590 Background: TP53 mutations ( TP53 MUT ) are known to be associated with adverse prognosis in acute...
Optimizing an NGS low-pass–based method to detect genomic instability as a PARP inhibitor predictive biomarker in high-grade serous ovarian cancer.
5567 Background: In high-grade serous ovarian cancer (HGSOC) PARP inhibitors constitute a standard treatment in tumors harboring Genomic Instability (GI)....
Clobazam as an add-on treatment for medically refractory brain tumor-related epilepsy.
e14038 Background: Over 25,000 patients receive a new diagnosis of a malignant primary brain tumor yearly and of those patients between 30-70% will experi...
A single center experience of PIK3CA and AKT inhibitors in patients with hormone receptor positive metastatic breast cancer.
e13051 Background: Currently there are 3 FDA- approved PI3K/AKT inhibitors: alpelisib, capivasertib and inavolisib. Management of off-tumor on-target side...
Trop2-targeted PET/CT with <sup>68</sup> Ga-MY6349 for the diagnosis of primary and metastatic breast cancer and evaluation towards patient stratification in Trop2-targeted ADCs.
1113 Background: Trop2-targeted ADCs have demonstrated promising efficacy and have been approved in patients with HR+HER2- and triple-negative breast canc...
Personalised artificial intelligence–based approach to assessing objective response to immunotherapy in patients with solid tumors.
e13640 Background: Predicting response to immune checkpoint inhibitors is a crucial need in real-world clinical practice that has not yet been met. Variou...
A transfer-learned hierarchical variational autoencoder model for computational design of anticancer peptides.
e13665 Background: Cancer is a leading cause of mortality globally, necessitating the development of effective therapies....
A real-world picture of biomarker testing in metastatic bladder cancer: A comprehensive assessment of 19,979 patients treated in the US and Europe.
4570 Background: Recent advances in the molecular characterization of bladder cancer (BC) have led to the development and approval of several targeted the...
Clinical and surgical outcomes of neoadjuvant targeted therapy in anaplastic and differentiated thyroid cancer.
e18143 Background: The use of targeted therapy in anaplastic thyroid cancer (ATC) and differentiated thyroid cancer (DTC) is limited to the advanced setti...
Rare incidence of immune-related gastritis and duodenitis in a single tertiary medical center: A diagnostic challenge.
e24118 Background: Cancer immunotherapy has emerged as a cornerstone of modern cancer treatment. While generally considered well-tolerated, some immune-re...
Design of a phase 1 trial of <i>Listeria</i> <i>monocytogenes</i> 11-T856-1313 tetanus toxoid (Lm-LLO-TT) for pancreatic ductal adenocarcinoma (PDAC).
e15115 Background: Pancreatic cancer is the third leading cause of cancer mortality in the USA. Despite advances in therapy, the prognosis remains poor. P...
Enhancing patient understanding of pathology reports: Insights from a large database of patient inquiries.
e13512 Background: The 21st Century Cures Act and the adoption of electronic health records have given patients immediate access to their diagnostic repor...
First-in-human phase 1/2a study of PBP1510 (anti-PAUF mAb) in advanced/metastatic pancreatic adenocarcinoma: Safety results from early combination cohorts.
e16363 Background: Pancreatic Adenocarcinoma Up-regulated Factor (PAUF), a protein overexpressed in pancreatic adenocarcinoma, contributes to metastasis a...
Unraveling survival disparities in primary central nervous system (CNS) lymphoma: An analysis of race, socioeconomic factors, and treatment outcomes using the Surveillance, Epidemiology, and End Results program (2000–2021).
2086 Background: Primary central nervous system lymphoma (PCNSL) is a rare B-cell non-Hodgkin lymphoma with survival outcomes influenced by treatment, dem...
Neoadjuvant therapy with mFOLFOXIRI combined with camrelizumab and bevacizumab for microsatellite stable, locally advanced rectal cancer: A single-arm, open-label phase II study.
e15633 Background: Patients with microsatellite stable (MSS) rectal cancer account for a high proportion with poor response to immunotherapy. The purpose...